Below The Knee | Market Signal

When Industry Restructures Around Wound Care: Mölnlycke Spins Off Surgical, SkinTE Enters, Enforcement Continues

Mölnlycke announced plans to separate its Operating Room Solutions and Gloves businesses into a standalone entity called Mölnlycke Surgical, leaving Wound Care and Antiseptics as a focused, independent company. The retained Wound Care and Antiseptics business generated approximately €1.3 billion in net sales with a ~38% EBITDA margin in 2025. This structural separation signals Mölnlycke's intent to sharpen investment and innovation focus in wound care. The message is clear: wound care is large enough, profitable enough, and competitive enough to stand alone.

At the same time, PolarityBio announced the FDA has accepted its Biologics License Application for SkinTE (autologous cutaneous multicellular units) for Wagner Grade 1 diabetic foot ulcers, granting Priority Review with a PDUFA date of March 16, 2027. The BLA is supported by the Phase III COVER DFUS II trial, which met its primary endpoint of complete wound closure within 12 weeks. If approved, SkinTE would represent a significant new entrant in the skin substitute/biologics segment for DFUs, intensifying competition in a market already crowded with CAMP and advanced biologics products.

But enforcement keeps tightening. A Tennessee optometrist, Helen Boerman of Brentwood Eye Care, was sentenced to 42 months in federal prison after submitting approximately $11 million in false Medicare claims for wound care products—primarily skin grafts—she neither properly purchased nor used, receiving $6.9 million in fraudulent reimbursements. The scheme involved splitting single-use graft products between patients while billing as if new products were used, and fabricating patient appointment records. This case underscores ongoing CMS and DOJ scrutiny of skin substitute and wound care billing practices.

The story this week is structural: large-cap medtech restructuring around wound care as standalone business unit, new autologous biologics entering the DFUS category, and federal enforcement demonstrating real consequences for billing fraud. When an industry powerhouse spins off surgery to focus on wound care, when FDA is evaluating new autologous therapies, and when prosecutors are putting people in federal prison for fraud, the category has arrived as a distinct business segment.

Here's the week.

Regulatory | Tennessee Optometrist Sentenced 42 Months for $11M Wound Care Medicare Fraud

Helen Boerman of Brentwood Eye Care in Brentwood, Tennessee, was sentenced to 42 months in federal prison after submitting approximately $11 million in false Medicare claims for wound care products—primarily skin grafts—she neither properly purchased nor used. The scheme resulted in $6.9 million in fraudulent reimbursements. Boerman split single-use graft products between patients while billing Medicare as if new products were used for each patient, and fabricated patient appointment records to support additional claims. This case underscores ongoing CMS and DOJ scrutiny of skin substitute and wound care billing practices, a high-risk area given the high reimbursement rates for advanced wound care products like skin grafts.

The BTK read: This is pattern enforcement, not anomaly. Skin substitute fraud is now prosecuted as federal crime with prison time. For medtech companies, DME suppliers, and billing teams, this case is a warning: documentation integrity, purchase records, and clinical justification are table stakes. The Boerman sentence signals DOJ is prioritizing wound care billing fraud. Expect more audits, more prosecutions, and faster enforcement against outliers. Companies and suppliers with defensible practices outperform those playing at margins.

Market | Mölnlycke Separates Surgical Unit, Wound Care Business Stands Alone

Mölnlycke announced plans to spin off its Operating Room Solutions and Gloves businesses into a standalone entity called Mölnlycke Surgical, leaving Wound Care and Antiseptics as a focused, independent company. The retained Wound Care and Antiseptics business generated approximately €1.3 billion in net sales and a ~38% EBITDA margin in 2025. This structural separation signals Mölnlycke's intent to sharpen investment and innovation focus in wound care, which could accelerate competitive activity in advanced wound dressings and NPWT markets.

The BTK read: Mölnlycke's spinoff is the clearest signal yet that wound care is large, profitable, and competitive enough to be a standalone business. €1.3B with 38% EBITDA margin is enterprise-scale profitability. The company is betting wound care deserves its own capital allocation, management focus, and strategic independence rather than subsidy from surgical margins. This signals confidence in category growth and signals to competitors that wound care is a distinct strategic priority. Watch for Mölnlycke Wound Care's first investor presentation post-spinoff.

Financial | Smith+Nephew Raises $700M in Bonds to Refinance 2030 Notes

Smith+Nephew raised $700 million through a bond issuance to refinance its existing 2030 notes, signaling active balance sheet management amid ongoing operational restructuring. This capital markets activity indicates the company is extending its debt maturity profile and managing liquidity as it continues its 12-point turnaround strategy.

The BTK read: SNN's refinance is balance sheet recalibration. The company is extending debt maturity to align with turnaround timeline. This buys runway for execution on PICO NPWT geographic expansion, Integrity Orthopaedics integration, and CAMP pricing adaptation.

Market | Zimmer Biomet Restructures Americas Leadership and Overhauls Sales Force

Zimmer Biomet restructured its Americas leadership team and announced a commercial overhaul effective October 1, 2026. The company is replacing independent contractor sales representatives with fully dedicated specialists across its 2,500-person U.S. sales force. Three executives were promoted and one position was eliminated as part of the streamlining.

The BTK read: Zimmer's contractor-to-dedicated shift is commercial model recalibration. For lower limb reconstruction and foot & ankle markets, this could affect contracting dynamics and market access strategies.

Regulatory | FDA Accepts SkinTE BLA with Priority Review for Diabetic Foot Ulcers

PolarityBio announced the FDA has accepted its Biologics License Application (BLA) for SkinTE (autologous cutaneous multicellular units) for Wagner Grade 1 diabetic foot ulcers, granting Priority Review with a PDUFA date of March 16, 2027. The BLA is supported by the pivotal Phase III COVER DFUS II trial, which met its primary endpoint of complete wound closure within 12 weeks. If approved, SkinTE would represent a significant new entrant in the skin substitute/biologics segment for DFUs, intensifying competition in a market already crowded with CAMP and advanced biologics products.

The BTK read: SkinTE's Priority Review and Phase III endpoint achievement is the clinical validation signal. Autologous cell therapy for DFU is differentiated pathway from off-the-shelf allografts. The March 16, 2027 PDUFA date means regulatory decision timeline is visible. If approved, SkinTE becomes another option in the crowded DFUS category, forcing existing players (allografts, synthetic scaffolds, topical therapies) to defend market share on efficacy, cost, and ease of use. Watch for reimbursement strategy and pricing announcement post-approval.

Market | Stryker Expands Foot & Ankle Portfolio With Prophecy and smartHEX Systems

Stryker expanded its foot and ankle innovation offerings with the Prophecy and smartHEX systems, reinforcing its position in the lower limb reconstruction and surgical planning space. These technologies support preoperative planning and implant alignment in foot and ankle procedures, increasingly relevant as diabetic limb salvage and deformity correction procedures grow. This expansion signals continued medtech investment in the foot and ankle segment.

The BTK read: Stryker's foot & ankle expansion is adjacency consolidation. Preoperative planning and implant alignment are workflow optimization plays. This positions Stryker for the growing limb salvage procedures where surgical precision matters. Watch for adoption in high-volume orthopedic centers.

Market | BioStem Technologies Presents Surgical Biologics Strategy at HC Wainwright

BioStem presented at H.C. Wainwright last week and is increasingly positioning itself around surgical biologics, following its acquisition of BioTissue's surgical and wound-care business earlier this year. The company is clarifying its strategic focus on regenerative medicine applications across surgical and wound-care use cases.

The BTK read: BioStem's surgical biologics positioning is portfolio clarification. The BioTissue acquisition gave them surgical and wound-care assets. Now they're signaling investor focus on regenerative applications. Watch for clinical trial announcements and reimbursement strategy clarity.

Regulatory | UltiMaker and Bioactivx Partner to Scale 3D-Printed Regenerative Wound Care

UltiMaker and Singapore-based startup Bioactivx have signed an MOU to co-develop scalable, on-demand 3D-printed wound care solutions, coinciding with Bioactivx receiving HSA (Health Sciences Authority) approval for its flagship Bioactiv Matrix product. Bioactiv Matrix is a synthetic, animal-free regenerative scaffold manufactured via a proprietary filament process in a certified cleanroom built on UltiMaker's platform. This development signals a growing role for additive manufacturing in wound care, potentially disrupting traditional skin substitute and wound matrix supply chains with digitally distributed, on-demand production.

The BTK read: UltiMaker/Bioactivx partnership is manufacturing infrastructure disruption. 3D-printed, on-demand wound care scaffolds could reshape supply chain from centralized batch manufacturing to distributed, digital production. This is early-stage but signals where manufacturing technology is heading. Watch for clinical validation and regulatory pathway expansion beyond Singapore.

Investment | ARPA-H Awards $62.7M for Agentic AI in Cardiovascular Heart Failure Care

ARPA-H has awarded $62.7 million over four years to companies including Tempus AI and Updoc to build an agentic AI system supporting heart failure patients between clinical visits under the ADVOCATE program. The initiative will develop regulatory frameworks with FDA for patient-facing clinical AI, targeting the nearly half of U.S. counties lacking cardiologist access. While focused on cardiovascular care broadly, this signals growing federal investment in AI-driven remote monitoring and care coordination that could influence vascular and wound care digital health reimbursement pathways.

The BTK read: ARPA-H's agentic AI investment is infrastructure play on remote monitoring and clinical decision support. The FDA regulatory framework development signals how autonomous clinical AI will be regulated and reimbursed. For vascular and wound care, this could shape future payment models for AI-assisted diagnostics and care coordination. Watch for FDA guidance and reimbursement policy announcements.

Woundcare, Limb Salvage, Foot and Ankle and Vascular, all scored, indexed and monitored. Real-time capital signals. Curated news and alerts. AI-powered queries. The way no market intelligence platform has done before.

intelligence.belowtheknee.co/sign-up →

BTK Wound Care Fund (5D): +0.005% | S&P 500: −0.25% | Dow Jones: −1.51% | NASDAQ: +0.32%

Top 5, five days:

Bottom 5, five days:

The BTK read: Fund flat while broader market declines. RCEL (+13.56%) leads on AVITA reimbursement clarity and commercial momentum. AXGN (+7.41%) holds on nerve repair positioning. INFU (+2.72%) stable on NPWT patient services strength. ORGO (−8.72%) under pressure on CAMP competition and SkinTE FDA entry. CELU (−9.93%) volatile on restructuring narrative. Bifurcation holds: specialists with clear pipelines and reimbursement pathways outperform generalists exposed to category-level competition and pricing pressure.

**Educational model portfolio. Not a real fund. Not investment advice. Performance is model-calculated and unaudited.

September 23–27 | Kuala Lumpur, Malaysia — WUWHS 2026 – World Union of Wound Healing Societies Congress — Kuala Lumpur Convention Centre

October 1–4 | Bengaluru, India — DFSICON 2026 — Hilton Garden Inn Bengaluru, Embassy Manyata Business Park

October 8–10 | New Delhi, India — ASVS–VSICON 2026 — Pullman & Novotel New Delhi Aerocity

October 15–18 | Las Vegas, NV — SAWC Fall 2026 — Caesars Palace

October 22–24 | Anaheim, CA — DFCon 2026 — JW Marriott

November 6 | Virtual — WoundCon Fall 2026

Early December (dates TBD) | San Antonio, TX — DFUpdate 2026 (ALPS)

December 9–12 | Phoenix, AZ — Desert Foot, Multi-Disciplinary Limb Salvage & Wound Care Conference

Not subscribed? newsletter.belowtheknee.co. Forward this to one person in your network who works in this space.

Next up: WUWHS in Kuala Lumpur in six days.

-Scott